Research Overview
GLOW Stack is a research blend supplied at 70mg combined peptide content, comprising three separately characterised research peptides: GHK-Cu, BPC-157 and TB-500. Each component is supplied at 99.0% purity by HPLC with batch-specific Certificates of Analysis including chromatograms, mass spectrometry verification and endotoxin testing.
GHK-Cu is a copper-binding tripeptide originally isolated from human plasma, investigated extensively in skin-biology and extracellular-matrix research. BPC-157 is a 15-residue partial sequence derived from a gastric protein, investigated in soft-tissue and gastrointestinal-mucosa research. TB-500 is a synthetic representation of the active region of thymosin beta-4, investigated in actin-binding and cytoskeletal-dynamics research. The blend is presented for laboratory research in which investigators wish to study these three peptide systems in parallel or as part of methodological comparisons.
The product is intended exclusively for in-vitro and laboratory research use and is not authorised as a medicinal product, cosmetic, food or supplement. Each component within the blend should be considered separately when designing experimental protocols, reviewing published methodology and consulting applicable institutional and national guidance for laboratory peptide research.
Mechanism Studied in Research
Each component of the GLOW Stack has been characterised in distinct research literatures, and investigators typically consider their pathways separately when designing studies. GHK-Cu has been investigated in skin-biology research as a copper-binding tripeptide that interacts with extracellular-matrix remodelling pathways, with documented effects in fibroblast cultures on collagen and glycosaminoglycan synthesis. In dermal fibroblast research it has been studied for modulation of matrix-metalloproteinase expression and tissue-inhibitor of metalloproteinase ratios, framing it as a model compound for extracellular-matrix homeostasis research.
BPC-157 has been characterised in soft-tissue and gastrointestinal-mucosa research as a pentadecapeptide partial sequence derived from a protein identified in gastric juice. In preclinical animal models it has been studied for interaction with nitric-oxide signalling, vascular endothelial growth-factor pathways and angiogenesis-related markers in tendon, ligament and mucosal injury research models.
TB-500 is a synthetic representation of the actin-binding region of thymosin beta-4 and has been characterised in actin-sequestration research, with documented capacity to bind G-actin monomers in vitro and modulate cytoskeletal dynamics. Wound-model and cardiac-tissue research has investigated its interaction with cell migration and angiogenesis pathways.
Research Applications
GLOW Stack research applications draw on the literatures of each component peptide and on emerging interest in multi-peptide methodology. In skin-biology research, GHK-Cu has been investigated in fibroblast culture and ex-vivo skin-explant models, with published methodology characterising its effects on collagen, elastin and glycosaminoglycan synthesis.
BPC-157 has been investigated in soft-tissue, tendon, gastric and wound-model research. In soft-tissue research, BPC-157 has been studied across more than a decade of preclinical work in tendon, ligament and muscle injury animal models, with documented interactions with nitric-oxide signalling and growth-factor pathways. TB-500 has been studied in actin-binding research that draws on the broader thymosin beta-4 literature, including investigations in cardiac repair and cell-migration models.
GLOW Stack is intended for methodological comparison research, where investigators may examine separate component effects or compare peptide systems under controlled laboratory conditions. The blend is designed for parallel laboratory investigation, although each peptide remains pharmacologically distinct.
Reconstitution Reference
GLOW Stack is supplied as a lyophilised powder containing the three component peptides and researchers reconstitute it using bacteriostatic water containing 0.9% benzyl alcohol. A common preparation is the addition of 2ml to a 70mg vial, yielding a combined concentration of 35mg per ml, with alternative volumes used at investigator discretion. Diluent should be added slowly down the inner wall of the vial without directing the stream onto the lyophilised cake. The vial should be left undisturbed to dissolve passively for several minutes, with gentle inversion if required. Vigorous shaking is not recommended.
Storage and Handling
Lyophilised GLOW Stack vials should be stored at minus 20 degrees Celsius in a dry, light-protected environment, with short-term storage between 2 and 8 degrees Celsius acceptable for several weeks prior to reconstitution. Reconstituted solutions should be refrigerated between 2 and 8 degrees Celsius and used within the stability window characterised by the laboratory’s QC programme. Repeated freeze-thaw cycles are not recommended.
References
[1] (2015). GHK peptide as a natural modulator of multiple cellular pathways in skin regeneration. BioMed Research International. PMID 26236730
[2] (2018). BPC-157 and pentadecapeptide BPC-157: theoretical and practical implications. Current Neuropharmacology. PMID 30045070
[3] (2006). Thymosin beta4 actin-sequestering protein promotes in repair injured tissues. Trends in Molecular Medicine. PMID 16750888
[4] (2007). Pentadecapeptide BPC-157 enhances the growth hormone receptor expression in tendon fibroblasts. Molecules. PMID 20204546
[5] (2020). Thymosin beta4 structure, function, and biological properties supporting current and future clinical applications. Annals of the New York Academy of Sciences. PMID 32055408